MCID: HRP008
MIFTS: 16

Herpes Simiae

Categories: Rare diseases

Aliases & Classifications for Herpes Simiae

MalaCards integrated aliases for Herpes Simiae:

Name: Herpes Simiae 49

Classifications:



Summaries for Herpes Simiae

MalaCards based summary : Herpes Simiae The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney.

Related Diseases for Herpes Simiae

Symptoms & Phenotypes for Herpes Simiae

Drugs & Therapeutics for Herpes Simiae

Drugs for Herpes Simiae (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 134678-17-4 60825
5
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
6
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
7
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
8
Oseltamivir Approved Phase 4,Phase 3,Phase 2 196618-13-0, 204255-11-8 65028
9
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
10
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
11
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
12
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
13
Peginterferon alfa-2b Approved Phase 4,Phase 3 215647-85-1, 99210-65-8
14
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2 142340-99-6 60871
15
Ethiodized oil Approved, Investigational Phase 4,Phase 2 8008-53-5
16
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 21645-51-2
17
Ethanol Approved Phase 4 64-17-5 702
18
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
19
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Ibuprofen Approved Phase 4 15687-27-1 3672
22
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
23
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
24
Thymalfasin Approved, Investigational Phase 4,Phase 1,Phase 2 62304-98-7
25
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
26
Ledipasvir Approved Phase 4,Phase 2,Phase 3 1256388-51-8 67505836
27
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
28 Dolutegravir Approved Phase 4 1051375-16-6 54726191
29 Adefovir Phase 4,Phase 3,Phase 2
30
Tenofovir Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
31 Clevudine Phase 4,Phase 3,Phase 2
32 Atorvastatin Calcium Phase 4 134523-03-8
33 Analgesics Phase 4,Phase 3
34 interferons Phase 4,Phase 3,Phase 2,Phase 1
35 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
36 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 1,Phase 2
37 gamma-Globulins Phase 4,Phase 3,Phase 1,Phase 2
38 Aluminum phosphate Phase 4
39 Cyclooxygenase Inhibitors Phase 4,Phase 3
40 Analgesics, Non-Narcotic Phase 4,Phase 3
41 Hepatitis C Antibodies Phase 4,Phase 2,Phase 3
42 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
43 Anesthetics Phase 4,Phase 2,Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 1
47 Anticholesteremic Agents Phase 4,Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 2
49 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Hypolipidemic Agents Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 586)

# Name Status NCT ID Phase Drugs
1 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
2 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
3 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
4 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
5 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
6 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
7 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
8 Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
9 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4 Mycophenolate Mofetil;Tacrolimus
10 Banlangen Granules Anti-seasonal Influenza Study Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
11 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
12 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
13 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
14 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4 Telbivudine
15 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
16 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
17 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
18 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
19 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
20 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
21 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
22 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
23 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
24 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
25 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
26 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
27 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
28 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
29 Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients Completed NCT02108444 Phase 4
30 TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA Completed NCT01732367 Phase 4 Lamivudine plus adefovir;Tenofovir
31 Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Completed NCT01788371 Phase 4 Telbivudine;Lamivudine
32 Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy Completed NCT02039362 Phase 4 Tenofovir DF
33 Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Completed NCT00371150 Phase 4 Entecavir
34 A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) Completed NCT02570191 Phase 4 Peginterferon alfa-2a
35 Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Completed NCT00662545 Phase 4 Entecavir with continued standard of care antiretroviral therapy;continued standard of care with tenofovir in addition to emtricitabine or lamivudine
36 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) Completed NCT00397540 Phase 4
37 A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program Completed NCT02791269 Phase 4 Peginterferon alfa-2a
38 Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules Completed NCT01259453 Phase 4
39 Long-term Study With Clevudine Completed NCT00558818 Phase 4 Clevudine
40 Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects Completed NCT02202473 Phase 4 Lamivudine;Lamivudine+Oxymatrine Capsules
41 Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection Completed NCT00127959 Phase 4 tenofovir;emtricitabine;zidovudine;efavirenz
42 Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder Completed NCT01847430 Phase 4
43 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Completed NCT01327547 Phase 4 Maraviroc;Placebo
44 A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) Completed NCT02604823 Phase 4 Peginterferon alfa-2a
45 A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B Completed NCT00436163 Phase 4 Peginterferon alfa-2a
46 Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA Completed NCT00637663 Phase 4 Entecavir;Lamivudine
47 Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents Completed NCT02250274 Phase 4
48 Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure Completed NCT01074645 Phase 4 Tenofovir disoproxil fumarate (TDF)
49 Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents Completed NCT00141999 Phase 4
50 An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B Completed NCT00467545 Phase 4 telbivudine

Search NIH Clinical Center for Herpes Simiae

Genetic Tests for Herpes Simiae

Anatomical Context for Herpes Simiae

MalaCards organs/tissues related to Herpes Simiae:

38
Liver, Testes, Kidney, T Cells, Bone, Bone Marrow, B Cells

Publications for Herpes Simiae

Articles related to Herpes Simiae:

# Title Authors Year
1
Recovery of herpes simiae (B virus) from both primary and latent infections in rhesus monkeys. ( 177038 )
1975
2
Latency of Herpes Simiae (B virus) in rabbits. ( 177039 )
1975
3
Heterogeneity in Herpes simiae (B virus) and some antigenic relationships in the herpes group. ( 4375486 )
1974

Variations for Herpes Simiae

Expression for Herpes Simiae

Search GEO for disease gene expression data for Herpes Simiae.

Pathways for Herpes Simiae

GO Terms for Herpes Simiae

Sources for Herpes Simiae

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....